List of Excipients in Branded Drug THIAMINE HYDROCHLORIDE INJECTION, SOLUTION

« Back to Dashboard

Generic Drugs Containing THIAMINE HYDROCHLORIDE INJECTION, SOLUTION

Company	Ingredient	NDC	Excipient
HF Acquisition Co LLC DBA HealthFirst	thiamine hydrochloride injection, solution	51662-1635	SODIUM HYDROXIDE
HF Acquisition Co LLC DBA HealthFirst	thiamine hydrochloride injection, solution	51662-1635	WATER

What are the Most Frequently-Used Excipients in THIAMINE HYDROCHLORIDE INJECTION, SOLUTION?

# Of NDCs	Excipient
1	SODIUM HYDROXIDE
1	WATER

Thiamine Hydrochloride Injection Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Thiamine hydrochloride injection is a low-complexity sterile vitamin product with limited formulation patent protection and substantial price pressure. The strongest commercial opportunities are in preservative-free presentations, shortage-resilient manufacturing, ready-to-administer packaging, hospital contract supply, and differentiated low-volume or high-concentration presentations. Excipient selection should prioritize chemical stability, sterility assurance, injection-site tolerability, and compatibility with intravenous, intramuscular, or subcutaneous administration.

What is thiamine hydrochloride injection?

Thiamine hydrochloride injection is a parenteral vitamin B1 product used to treat or prevent thiamine deficiency when oral administration is not appropriate. U.S. products are commonly supplied as aqueous solutions at 100 mg/mL, although strength, fill volume, route, and packaging differ by manufacturer.[1]

The active ingredient is thiamine hydrochloride, a water-soluble salt. The formulation is generally simple:

Formulation element	Typical role
Thiamine hydrochloride	Active pharmaceutical ingredient
Water for Injection	Vehicle
Sodium chloride	Tonicity adjustment, when used
Hydrochloric acid or sodium hydroxide	pH adjustment
Nitrogen or other headspace control	Oxygen reduction, where used
Preservative	Used only in selected multidose presentations

Many commercial presentations are preservative-free and packaged in single-dose vials or ampules. Product-specific labels must be reviewed because inactive ingredients, pH ranges, concentrations, storage conditions, and container systems are not uniform across manufacturers.[1]

Which excipients are most suitable for thiamine hydrochloride injection?

The preferred strategy is a minimal-excipient, aqueous formulation. Each added excipient increases extractables, compatibility, toxicology, and regulatory burden without necessarily improving product performance.

Water for Injection

Water for Injection is the primary vehicle. It must comply with compendial requirements for chemical quality, microbial control, and bacterial endotoxins. The manufacturing process must control bioburden before sterilizing filtration or terminal sterilization.

Sodium chloride

Sodium chloride can improve isotonicity and reduce injection-site discomfort. It may be useful for intramuscular or intravenous formulations, but it is not mandatory in every product. The required quantity depends on the thiamine hydrochloride concentration, target osmolality, route, and final pH.

A sodium-chloride-containing presentation may be commercially useful for hospital protocols that favor near-isotonic products. It can also reduce the need for bedside dilution. The tradeoff is a more complex formulation and greater risk of precipitation or altered stability if the formulation is combined with other drugs.

pH adjusters

Hydrochloric acid and sodium hydroxide are standard pH adjusters. Thiamine is sensitive to alkaline conditions and may undergo degradation under unsuitable pH, temperature, light, or oxygen exposure. A controlled acidic formulation is generally more practical than an aggressively buffered system.

A strong buffer system may create compatibility problems and increase ionic load. For this product, a low-capacity pH-adjustment approach is usually preferable to a heavily buffered formulation unless stability data support the change.

Buffers

Potential buffers include citrate, acetate, or phosphate systems. Their use should be justified by demonstrated stability or administration requirements.

A buffer can improve pH control during storage, but it may also:

• Increase osmolality.
• Affect degradation pathways.
• Change compatibility with infusion fluids.
• Increase the risk of precipitation after dilution.
• Create additional extractables or analytical requirements.

For a standard thiamine hydrochloride injection, a buffer-free or lightly adjusted formulation has a stronger commercial rationale than a highly buffered product.

Antimicrobial preservatives

Benzyl alcohol, parabens, phenol, and related preservatives may be considered for multidose containers, but preservative-free packaging is generally more attractive for hospital and emergency use.

Preservatives create additional safety and labeling considerations, particularly for neonates, infants, pregnant patients, and patients receiving repeated parenteral doses. A preservative-free product can support intensive-care, emergency-department, and pediatric procurement requirements, even if it requires single-dose packaging.

How should thiamine hydrochloride injection be optimized for stability?

Stability work should focus on pH, light, oxygen, temperature, concentration, and container interaction.

Variable	Commercial significance	Development approach
pH	Controls degradation and color formation	Establish a narrow target range with forced-degradation data
Light	Thiamine solutions may be light-sensitive	Use amber containers or secondary light protection where justified
Oxygen	May contribute to oxidative degradation	Evaluate nitrogen headspace and low-oxygen filling
Temperature	Accelerates degradation	Define refrigerated and controlled-room-temperature options
Concentration	Affects degradation rate and tonicity	Compare 50, 100, and 200 mg/mL candidates
Container closure	Can affect adsorption, leachables, and oxygen ingress	Screen glass, polymer vials, ampules, and prefilled syringes
Dilution	Determines hospital usability	Test common infusion fluids and hold times

The development program should include assay, related substances, color, pH, particulate matter, sterility, bacterial endotoxins, container closure integrity, and visible and subvisible particles. USP requirements for sterile products, particulate matter, and bacterial endotoxins are central to release and stability testing.[2]

Light protection

Amber glass or an opaque secondary package may provide a low-cost differentiation point. A manufacturer should avoid unnecessary light-protection claims unless supported by photostability testing under ICH Q1B conditions.[3]

Oxygen control

Nitrogen purging can reduce oxygen exposure, but it adds manufacturing controls and may not produce a meaningful commercial benefit if the formulation is already stable in the selected container. Oxygen-control claims should be tied to comparative stability results, not used as a marketing substitute for data.

Container selection

Glass ampules have a long history in injectable products but create breakage and administration risks. Single-dose glass vials may improve hospital handling and allow needle-based withdrawal. Polymer containers or prefilled syringes can improve workflow but require more extensive extractables, leachables, compatibility, and device testing.

What formulations are protected by thiamine hydrochloride injection patents?

Standard thiamine hydrochloride injection has a limited basis for composition-of-matter patent protection because the active ingredient is an established vitamin salt and the formulation is generally conventional.

Potentially protectable subject matter may include:

1. A narrowly defined pH and concentration range.
2. A stability-enhancing excipient combination.
3. A novel oxygen-control or light-protection system.
4. A prefilled syringe or autoinjector presentation.
5. A ready-to-administer infusion format.
6. A manufacturing process that reduces degradation or particulate formation.
7. A combination product with another injectable vitamin or nutrient.

A formulation patent would need to establish an unexpected stability, tolerability, manufacturability, or administration benefit. Broad claims covering thiamine hydrochloride, water, sodium chloride, and pH adjustment would face significant validity and obviousness challenges if similar commercial products and technical disclosures already exist.

What is the Orange Book status of thiamine hydrochloride injection?

The Orange Book is relevant to approved prescription drug products and generic equivalence, but the commercial risk profile for standard thiamine hydrochloride injection is generally different from that of a recently approved small-molecule drug.

A conventional product is more likely to compete through an abbreviated new drug application if the reference product, strength, dosage form, route, and labeling support an ANDA pathway. FDA evaluates inactive ingredients in injectable products for safety and suitability, and the FDA Inactive Ingredient Database is a key reference for excipient precedent.[4]

Potential barriers include:

• No suitable reference-listed drug for the intended presentation.
• A novel concentration or delivery system.
• Different inactive ingredients that require additional justification.
• A multidose container with preservative-related safety concerns.
• Device functionality in a prefilled syringe.
• Sterility, particulate, or container-closure deficiencies.

The absence of a meaningful composition patent does not eliminate regulatory risk. Injectable products face higher manufacturing and inspection risk than many oral generics.

When does thiamine hydrochloride injection lose exclusivity?

For standard thiamine hydrochloride injection, exclusivity is generally not the primary commercial barrier. The active ingredient has been marketed for decades, and competition is principally governed by FDA approval, manufacturing capacity, supply contracts, and product quality.

The relevant market-entry questions are:

Issue	Likely impact
New chemical entity exclusivity	Not relevant to an established vitamin product
Orphan exclusivity	Generally not relevant to standard thiamine injection
Patent term	Usually limited relevance for conventional formulations
Paragraph IV challenge	Relevant only if an ANDA applicant certifies against listed patents
180-day generic exclusivity	Could affect a first approved ANDA if statutory conditions are met
Manufacturing approval	Major practical barrier
Hospital contracting	Can delay commercial uptake after approval

A Paragraph IV challenge would have commercial significance only if an approved reference product has relevant Orange Book-listed patents. For a conventional thiamine hydrochloride injection, the more material risks are supply interruptions, inspection findings, recalls, and contract displacement.

What patent litigation and settlement risks affect thiamine hydrochloride injection?

Patent litigation risk is likely to be low for a conventional formulation. The principal litigation scenarios would involve:

• A novel ready-to-use presentation.
• A prefilled delivery device.
• A combination product.
• A formulation with a narrow stability-enhancing excipient system.
• Manufacturing-process claims.
• Trade-secret disputes involving sterile processing or impurity control.

A Paragraph IV settlement would matter only if a branded sponsor had enforceable listed patents or other commercially relevant rights. For a basic thiamine injection, a standard generic launch is more likely to proceed without a major patent settlement than in therapeutic classes with dense formulation and method-of-use patent estates.

How strong is the patent estate for thiamine hydrochloride injection?

The patent estate is likely weak for the basic drug product and potentially stronger for differentiated delivery formats.

Product concept	Patent strength	Commercial defensibility
Conventional aqueous vial	Low	Low
Preservative-free single-dose ampule	Low to moderate	Primarily operational
High-concentration formulation	Moderate if stability is unexpected	Depends on data
Prefilled syringe	Moderate	Device and usability claims
Ready-to-administer infusion bag	Moderate	Manufacturing and packaging claims
Combination vitamin injection	Moderate	Product-specific and clinical claims
Novel depot or sustained-release formulation	Potentially high	Requires extensive development

A company seeking durable protection should focus on a measurable technical advantage. Patent claims tied only to routine excipients and conventional concentration ranges are unlikely to provide strong exclusionary power.

What are the best commercial opportunities for thiamine hydrochloride injection?

Shortage-resilient hospital supply

Hospitals purchase injectable vitamins based on reliable availability, product quality, packaging, and contract terms. A second-source manufacturer with validated sterile capacity can compete even without a novel formulation.

The commercial proposition should emphasize:

• Consistent supply.
• Multiple vial and ampule sizes.
• Preservative-free options.
• Clear storage instructions.
• Barcoded unit-dose packaging.
• Rapid replacement for discontinued or constrained products.

Ready-to-administer presentations

A prefilled syringe or small-volume ready-to-administer format can reduce pharmacy compounding and bedside preparation. The product would require device compatibility, dose accuracy, extractables and leachables, container-closure integrity, and human-factors work.

This format has greater differentiation potential than a standard vial but also carries higher development cost and regulatory complexity.

High-concentration products

A 100 mg/mL or higher-strength presentation may reduce injection volume and improve emergency use. The commercial case depends on tolerability, stability, compatibility, and demand from hospitals using high-dose replacement protocols.

A high-concentration product should not be positioned solely on volume reduction. The manufacturer would need evidence that the presentation reduces preparation time or medication-use burden without increasing administration risk.

Pediatric and neonatal supply

Preservative-free, low-volume presentations may have value in pediatric and neonatal settings. These markets are sensitive to excipient safety, dose accuracy, container usability, and availability in small fill volumes.

Combination vitamin products

Thiamine can be combined commercially with other injectable vitamins or nutrients, but combination products introduce compatibility and regulatory risks. The formulation must address pH, degradation, precipitation, dosing logic, and clinical need. A combination product may have more defensible intellectual property than a single-ingredient vial, but the development program is materially more complex.

How does thiamine hydrochloride injection compare with competing vitamin injections?

Attribute	Thiamine HCl injection	Other injectable vitamins
Formulation complexity	Low to moderate	Varies; fat-soluble vitamins are often more complex
Patent barrier	Generally low	Higher for novel combinations and delivery systems
Sterility burden	High	High
Excipient sensitivity	pH, light, oxygen, tonicity	May include surfactants, oils, antioxidants, or solubilizers
Differentiation opportunity	Packaging and workflow	Formulation, delivery, and combination products
Likely buyer	Hospitals, emergency departments, pharmacies	Hospitals, specialty clinics, nutrition services
Main competitive factor	Supply reliability and price	Product-specific clinical and handling requirements

Thiamine has an advantage in formulation simplicity. Its disadvantage is limited ability to command premium pricing without a meaningful administration or supply-chain improvement.

What FDA regulatory requirements apply to thiamine hydrochloride injection?

A U.S. product must meet requirements for sterile injectable manufacturing, including current good manufacturing practice, process validation, environmental controls, aseptic processing or validated terminal sterilization, container-closure integrity, and release testing.[5]

Development priorities include:

1. Establishing a discriminating stability-indicating assay.
2. Demonstrating sterility and bacterial endotoxin control.
3. Controlling visible and subvisible particulates.
4. Confirming compatibility with proposed diluents.
5. Evaluating administration by each labeled route.
6. Qualifying all container-closure components.
7. Assessing extractables and leachables for polymer systems.
8. Validating the sterilization or aseptic process.
9. Demonstrating inactive-ingredient suitability through FDA precedent or supporting data.[4]

A product seeking approval through an ANDA should minimize unnecessary differences from the reference product. A product using a novel excipient, novel device, or materially different presentation may require a more complex regulatory strategy.

What generic launch scenarios exist for thiamine hydrochloride injection?

Standard vial launch

This is the lowest-risk commercial pathway. It depends on manufacturing cost, supply reliability, and access to group purchasing organizations and hospital distributors.

Preservative-free expansion

A manufacturer can begin with a single-dose product and add alternate fill volumes or strengths. This supports hospital formulary penetration without requiring a fundamentally new formulation.

Ready-to-administer launch

This offers greater differentiation and potentially stronger customer retention. It requires higher investment in device development and production automation.

Contract manufacturing and private label

Sterile injectable capacity is valuable to companies without their own facilities. A contract manufacturer can supply thiamine products under multiple labels, but quality agreements, capacity allocation, and change-control discipline are critical.

What geographic markets offer the best opportunity?

The most attractive markets are those with hospital injectable shortages, centralized procurement, and limited local sterile manufacturing capacity. The United States offers a large regulated market but has significant compliance and contracting barriers. European markets may reward preservative-free and standardized presentations but require national pricing and reimbursement strategies. Emerging markets may offer volume growth but often place greater emphasis on price, local registration, and government procurement.

Geographic expansion should prioritize products that can use the same validated formulation and container system across jurisdictions. Changes to concentration, excipients, labeling, or route can eliminate the efficiency of a single global dossier.

Key Takeaways

• Thiamine hydrochloride injection is generally a low-patent-barrier, high-compliance sterile product.
• The preferred formulation is usually a simple aqueous system with controlled pH and limited excipients.
• Sodium chloride may improve tonicity and usability but should be justified by route and stability data.
• Preservative-free single-dose packaging is commercially attractive for hospital and pediatric use.
• The strongest differentiation opportunities are ready-to-administer systems, high-concentration products, and shortage-resilient supply.
• Standard composition patents are unlikely to provide durable protection without unexpected technical results.
• Generic entry risk is driven more by FDA manufacturing approval, supply reliability, and contracting than by patent litigation.
• The commercial strategy should combine a low-cost standard vial with a differentiated presentation that improves medication-use workflow.

FAQs About Thiamine Hydrochloride Injection Excipient Strategy

Is sodium chloride required in thiamine hydrochloride injection?

No. Sodium chloride may be used to adjust tonicity, but the need depends on concentration, route, osmolality, and the approved formulation.

Can benzyl alcohol be used in thiamine hydrochloride injection?

It may be used in selected multidose products, but preservative safety must be evaluated for the intended population. Preservative-free packaging is generally more suitable for neonatal, pediatric, and high-risk hospital use.

Does thiamine hydrochloride injection have strong formulation patent protection?

Conventional aqueous vial formulations generally have limited patent strength. Stronger protection may be possible for novel delivery systems, combination products, or formulations with demonstrated unexpected stability advantages.

Is a prefilled syringe commercially attractive for thiamine injection?

Yes, if it reduces preparation time and medication-use risk. The presentation requires additional device, usability, extractables, stability, and container-closure development.

What is the main barrier to launching a generic thiamine injection?

The main barrier is validated sterile manufacturing capacity. Regulatory approval, particulate control, container integrity, supply reliability, and hospital contracting are usually more important than active-ingredient patent protection.

References

1. DailyMed. (n.d.). Thiamine hydrochloride injection, solution: Prescribing information. U.S. National Library of Medicine.
2. United States Pharmacopeia. (2024). General chapters <1>, <71>, <85>, <788>, and <790>. United States Pharmacopeial Convention.
3. International Council for Harmonisation. (1996). ICH Q1B: Photostability testing of new drug substances and products.
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
5. U.S. Food and Drug Administration. (2004). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice.